Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Par Pharmaceutical Companies, a US based specialty pharmaceutical company, has entered into an exclusive supply and distribution agreement with AstraZeneca in the US to distribute the authorised generic version of AstraZeneca's Accolate (zafirlukast).
Subscribe to our email newsletter
Par Pharma began shipping 10mg and 20mg strengths of Zafirlukast tablets on 19 November 2010.
Accolate, an oral prescription medicine used to treat asthma, works by blocking substances in the body called leukotrienes, which may contribute to the asthma symptoms.
Zafirlukast tablets are indicated for the prophylaxis and chronic treatment of asthma in adults and children 5 years of age and older.
Par Pharmaceutical Companies, through its wholly-owned subsidiary’s two operating divisions, Par Pharmaceutical and Strativa Pharmaceuticals, develops, manufactures and markets higher-barrier-to-entry generic drugs and niche, innovative proprietary pharmaceuticals.